{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Nerve+Tissue&page=3",
    "query": {
      "condition": "Neoplasms, Nerve Tissue",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 5235,
    "total_pages": 524,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Nerve+Tissue&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Nerve+Tissue&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T14:25:43.752Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02388659",
      "title": "Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Malignant Gliomas",
        "Oligodendrogliomas",
        "Astrocytomas"
      ],
      "interventions": [
        {
          "name": "3 Tesla scanning",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 142,
      "start_date": "2014-02",
      "completion_date": "2021-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-10-06T14:25:43.752Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02388659"
    },
    {
      "nct_id": "NCT03375320",
      "title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Functioning Pancreatic Neuroendocrine Tumor",
        "Intermediate Grade Lung Neuroendocrine Neoplasm",
        "Locally Advanced Digestive System Neuroendocrine Neoplasm",
        "Locally Advanced Digestive System Neuroendocrine Tumor G1",
        "Locally Advanced Lung Neuroendocrine Neoplasm",
        "Locally Advanced Pancreatic Neuroendocrine Tumor",
        "Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm",
        "Low Grade Lung Neuroendocrine Neoplasm",
        "Lung Neuroendocrine Tumor",
        "Lung Neuroendocrine Tumor G2",
        "Metastatic Digestive System Neuroendocrine Neoplasm",
        "Metastatic Digestive System Neuroendocrine Tumor G1",
        "Metastatic Lung Neuroendocrine Neoplasm",
        "Metastatic Lung Neuroendocrine Tumor",
        "Metastatic Pancreatic Neuroendocrine Neoplasm",
        "Metastatic Pancreatic Neuroendocrine Tumor",
        "Metastatic Thymus Neuroendocrine Neoplasm",
        "Neuroendocrine Neoplasm",
        "Neuroendocrine Tumor",
        "Neuroendocrine Tumor G2",
        "Non-Functioning Pancreatic Neuroendocrine Tumor",
        "Pancreatic Serotonin-Producing Neuroendocrine Tumor",
        "Thymus Neuroendocrine Tumor",
        "Unresectable Digestive System Neuroendocrine Neoplasm",
        "Unresectable Digestive System Neuroendocrine Tumor G1",
        "Unresectable Lung Neuroendocrine Neoplasm",
        "Unresectable Pancreatic Neuroendocrine Neoplasm",
        "Unresectable Thymus Neuroendocrine Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 298,
      "start_date": "2018-10-26",
      "completion_date": "2027-09-01",
      "has_results": true,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-06T14:25:43.752Z",
      "location_count": 432,
      "location_summary": "Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 289 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03375320"
    },
    {
      "nct_id": "NCT02661282",
      "title": "Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus Positive",
        "Glioblastoma",
        "Gliosarcoma",
        "Malignant Glioma",
        "Recurrent Brain Neoplasm",
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2016-06-01",
      "completion_date": "2022-02-23",
      "has_results": true,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-10-06T14:25:43.752Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02661282"
    },
    {
      "nct_id": "NCT01989572",
      "title": "Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Iris Melanoma",
        "Medium/Large Size Posterior Uveal Melanoma",
        "Mucosal Melanoma",
        "Ocular Melanoma With Extraocular Extension",
        "Recurrent Melanoma",
        "Recurrent Uveal Melanoma",
        "Small Size Posterior Uveal Melanoma",
        "Stage IIA Cutaneous Melanoma AJCC v6 and v7",
        "Stage IIA Uveal Melanoma AJCC v7",
        "Stage IIB Cutaneous Melanoma AJCC v6 and v7",
        "Stage IIB Uveal Melanoma AJCC v7",
        "Stage IIC Cutaneous Melanoma AJCC v6 and v7",
        "Stage IIIA Cutaneous Melanoma AJCC v7",
        "Stage IIIA Uveal Melanoma AJCC v7",
        "Stage IIIB Cutaneous Melanoma AJCC v7",
        "Stage IIIB Uveal Melanoma AJCC v7",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IIIC Uveal Melanoma AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Stage IV Uveal Melanoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tyrosinase Peptide",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 815,
      "start_date": "2000-02-23",
      "completion_date": "2013-01-31",
      "has_results": true,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-10-06T14:25:43.752Z",
      "location_count": 148,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 117 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01989572"
    },
    {
      "nct_id": "NCT01789281",
      "title": "Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Sandostatin LAR Depot",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2013-05-14",
      "completion_date": "2020-08-28",
      "has_results": true,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-10-06T14:25:43.752Z",
      "location_count": 13,
      "location_summary": "Little Rock, Arkansas • Greenwood Village, Colorado • Stamford, Connecticut + 10 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01789281"
    },
    {
      "nct_id": "NCT00521053",
      "title": "Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "PV-10 (10% rose bengal disodium)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Provectus Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2007-09",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2014-08-25",
      "last_synced_at": "2026-10-06T14:25:43.752Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Louisville, Kentucky • Bethlehem, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Bethlehem",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00521053"
    },
    {
      "nct_id": "NCT00410657",
      "title": "Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Chronic Myeloproliferative Disorders",
        "Gestational Trophoblastic Tumor",
        "Graft Versus Host Disease",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "alemtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 53,
      "start_date": "2006-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-05-14",
      "last_synced_at": "2026-10-06T14:25:43.752Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00410657"
    },
    {
      "nct_id": "NCT05229601",
      "title": "A Study of HFB301001 in Adult Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Soft Tissue Sarcoma",
        "Renal Cell Carcinoma",
        "Uterine Carcinosarcoma",
        "Hepatocellular Carcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "HFB301001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HiFiBiO Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2022-04-20",
      "completion_date": "2024-05-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-10-06T14:25:43.752Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05229601"
    },
    {
      "nct_id": "NCT00389090",
      "title": "A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma",
        "Astrocytoma",
        "Oligodendroglioma",
        "Oligoastrocytoma"
      ],
      "interventions": [
        {
          "name": "Temozolomide and O6-Benzylguanine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Keryx / AOI Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2006-10",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2012-02-09",
      "last_synced_at": "2026-10-06T14:25:43.752Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Orlando, Florida • Chicago, Illinois + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00389090"
    },
    {
      "nct_id": "NCT04295759",
      "title": "INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma",
        "Anaplastic Oligodendroglioma",
        "DIPG",
        "High-grade Astrocytoma NOS",
        "CNS Primary Tumor, NOS (Malignant Glioma)"
      ],
      "interventions": [
        {
          "name": "INCB7839",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pediatric Brain Tumor Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 13,
      "start_date": "2020-07-27",
      "completion_date": "2026-09-08",
      "has_results": true,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-06T14:25:43.752Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04295759"
    }
  ]
}